Results
GoodRx Holdings Inc.
10/28/2024 | Press release | Distributed by Public on 10/28/2024 06:09
IQVIA CFO brings 39 years of healthcare and finance expertise to GoodRx Form 8 K
IQVIA CFO brings 39 years of healthcare and finance expertise to GoodRx
SANTA MONICA, Calif. October 28, 2024 - GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our,"
"GoodRx" or the "Company"), the leading prescription savings platform in the U.S., today announced the
election of Ronald E. Bruehlman to its Board of Directors, effective November 8, 2024. Mr. Bruehlman
brings to GoodRx 39 years of finance experience in the healthcare services, industrial and petroleum
industries. He currently serves as Chief Financial Officer of IQVIA, a global provider of advanced
analytics, technology solutions, and contract research. Prior to IQVIA, he served as CFO of IMS Health
and had a 23-year career at United Technologies Corporation, where he held multiple senior finance
leadership roles of increasing responsibility. Mr. Bruehlman previously served on the board of directors
of Atotech Ltd., Q-Squared Solutions, and Clipper Windpower.
"We are thrilled to welcome Mr. Bruehlman to the GoodRx Board. His extensive expertise leading
financial strategies for public and private healthcare and technology companies is a perfect match for
GoodRx as we navigate the complex healthcare market," said Trevor Bezdek, GoodRx co-founder and
Chairman of the Board. "Mr. Bruehlman's deep financial insight and strategic acumen will be critical as
we continue to focus on sustainable and profitable revenue growth, aiming to enhance affordability and
access to prescription medications across the country. His leadership will ensure the highest standards
of financial management and strategic risk assessment as we drive forward our mission."
Mr. Bruehlman will also serve as the chairperson of the Board's Audit and Risk Committee, following
Julie Bradley's resignation as a member of GoodRx's Board of Directors effective on November 8, 2024.
About GoodRx
GoodRx is the leading prescription savings platform in the U.S. Trusted by more than 25 million
consumers and 750,000 healthcare professionals annually, GoodRx provides access to savings and
affordability options for generic and brand-name medications at more than 70,000 pharmacies
nationwide, as well as comprehensive healthcare research and information. Since 2011, GoodRx has
helped consumers save over $75 billion on the cost of their prescriptions.
GoodRx periodically posts information that may be important to investors on its investor relations
website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material
nonpublic information and for complying with our disclosure obligations under Regulation FD.
Accordingly, investors and potential investors are encouraged to consult GoodRx's website regularly for
important information, in addition to following GoodRx's press releases, filings with the Securities and
Exchange Commission ("SEC") and public conference calls and webcasts. The information contained on,
or that may be accessed through, GoodRx's website is not incorporated by reference into, and is not a
part of, this press release.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements, including, without
limitation, statements regarding the anticipated contributions from Ronald E. Bruehlman in his
directorship and expected benefits to the Company and our Board. These statements are neither
promises nor guarantees, but involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements to be materially different from
any future results, performance or achievements expressed or implied by the forward-looking
statements, including, but not limited to, risks relating to our ability to attract and retain talent and the
important factors discussed under the caption "Risk Factors" in GoodRx's Annual Report on Form 10-K
for the year ended December 31, 2023, and our other filings with the SEC. Any such forward-looking
statements are based on current expectations, projections and estimates as of the date of this press
release. While we may elect to update such forward-looking statements at some point in the future, we
disclaim any obligation to do so, even if subsequent events cause our views to change.
Investor Contact
Media Contact